GSK Announces Efficacy of Arexvy Vaccine against Respiratory Syncytial Virus (RSV) in Adults

by worldysnews
2 comments




RSV Vaccine Shows Promising Results in Phase III Trial

#fullscreen input[type="checkbox"]:not(:checked) ~ #fullscreen label:before { content: "25B2"; }

#fullscreen input[type="checkbox"]:checked ~ #fullscreen label { margin-bottom: 0; }

#fullscreen input[type="checkbox"]:checked ~ #fullscreen label:hover { color: #666; cursor: pointer; }

#fullscreen input[type="checkbox"]:checked ~ #fullscreen label:hover:before { content: "25B2"; }

#fullscreen input[type="checkbox"]:not(:checked) ~ #fullscreen label:hover:before { content: "25BC"; }

#cookie-notice { background-color: #f2f2f2; padding: 20px; margin-bottom: 20px; }

#cookie-notice h3 { font-size: 18px; margin-bottom: 10px; }

#cookie-notice p { margin-bottom: 0; }

#newsletter { background-color: #f2f2f2; padding: 20px; }

#newsletter p { margin-bottom: 0; }


Thursday, June 22, 2023

You may also like

2 comments

Madison June 22, 2023 - 11:20 am

This is great news! GSK’s Arexvy vaccine showcasing efficacy against RSV in adults marks a significant step forward in preventing the spread of this respiratory virus. Promising results indeed!

Reply
Juliet June 22, 2023 - 11:20 am

This is fantastic news! GSK’s Arexvy vaccine showing efficacy against RSV in adults is a significant breakthrough in combating this respiratory virus. Exciting times ahead for improved prevention and protection.

Reply

Leave a Comment

Wrodlys News